Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VALIC Company I Health Sciences Fund (VCHSX)

20.21
Net Asset Value
-1.80%
1 Day
-20.43%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
No Load
Sales Expenses
1.09%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital growth. The fund normally invests at least 80% of net assets in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed "health sciences"). It can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund may invest up to 35% of its total assets in foreign stocks, which include non-dollar denominated securities traded outside the U.S.

Performance

1 month-2.37% 3 years+16.56%
3 months+3.53% 5 years+24.60%
1 year-3.96% Since inception+10.87%
Data through --

Peer Comparisonvs. Health

 VCHSXCategory
Performance 5-yr return+24.60%+17.07%
Expense ratio1.09%1.19%
Risk 5 year sharpe ratio1.311.21
Net assets$805.4M$233.9M
Average market cap$22.9B$31.2B
Average P/E24.118.7
Portfolio turnover31%31%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyVALIC
Fund manager & tenureTaymour Tamaddon / 3 Years
Minimal initial investment$0.00
Minimum IRA investment--

Holdings

U.S. stock94.25%
International stock3.30%
Cash1.68%
Other0.60%
Fixed income0.16%
Top 5 Sectors
Portfolio weighting
Healthcare 93.57%
Consumer service 1.09%
Industrial materials 0.89%
Financial service 0.35%
Hardware 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth4.41%
HUM Humana Inc4.33%
AET Aetna4.25%
AGN Allergan4.04%
BDX Becton Dickinson and Co3.66%
BMY Bristol-Myers Squibb3.62%
CI Cigna Corp3.07%
GILD Gilead Sciences2.94%
MCK McKesson Corp2.86%
TMO Thermo Fisher Scientific Inc2.73%

Partner Offers